The role of sustained-released alfuzosin in the treatment of acute urinary retention

Abstract

To see whether the use of alfirzosin l0 mg will increase the success rate of trial without catheter (TWOC) after an attack of acute urinary retention (AUR) retated to benign prostatic hyperplasia (BPH). One hundred patients with acute urinar;r retention due to BPH were consented and enrolled in this prospective ,randomized ,placeb+controlled  trial- After catheterization,  50 patients were given sustained release alfumsin l0 mg once daily,while the other 50 received placebo. The catheter was removed after three days of treahnent for trial without catheter (TWOC)- The main outcome measurements  were succ€ss or failure of TWOC. After removal of the catheter, 64% of patients receiving alfirzosin voided successfully compared to 36yo of patients on placebo; the differences being statistically significant at (p<0-05). The mean age of patients who successfully voided, regardless of h€atment, was 67.6 years and 69.7 yats for those who failed to void which is statistically not silrrificant Regarding retention volume, there was a significant difference (P<0'05) between the two groups (8E7.5 ml vs. 994.4 ml). The present tudy coclude that trial without catheter after three days of catheterization is a good practice for BPH men with AUR - However, using alfuzosin l0 mg once daily prior to calheter removal considerably increased the chance of successful TWOC especially if used in patients with low r€tention volume and younger age group.